{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:33:05Z","timestamp":1785000785421,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01359-w","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:06:48Z","timestamp":1759759608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Ali","family":"Alsugair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-4714","authenticated-orcid":false,"given":"Estefania","family":"Gauto Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4345-8770","authenticated-orcid":false,"given":"Mohammad M.","family":"Alhousani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9979-7923","authenticated-orcid":false,"given":"Saubia","family":"Fathima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-1954","authenticated-orcid":false,"given":"Abiola","family":"Bolarinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-1708","authenticated-orcid":false,"given":"James","family":"Foran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9887","authenticated-orcid":false,"given":"Abishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sproat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aasiya","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Slack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Porrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-5440","authenticated-orcid":false,"given":"Madiha","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-3830","authenticated-orcid":false,"given":"Saad","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5359-336X","authenticated-orcid":false,"given":"Mithun Vinod","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan B.","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-662X","authenticated-orcid":false,"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.27271","volume":"99","author":"MM Patnaik","year":"2024","unstructured":"Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management. Am J Hematol. 2024;99:1142\u201365.","journal-title":"Am J Hematol"},{"key":"1359_CR4","first-page":"60","volume":"12","author":"A Bangolo","year":"2024","unstructured":"Bangolo A, Amoozgar B, Thapa A, Bajwa W, Nagesh VK, Nyzhnyk Y, et al. Survival outcomes of U.S. patients with CMML: a two-decade analysis from the SEER database. Med Sci (Basel). 2024;12:60.","journal-title":"Med Sci (Basel)"},{"key":"1359_CR5","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/S2352-3026(20)30374-4","volume":"8","author":"L Pleyer","year":"2021","unstructured":"Pleyer L, Leisch M, Kourakli A, Padron E, Maciejewski JP, Xicoy Cirici B, et al. Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. Lancet Haematol. 2021;8:e135\u2013e48.","journal-title":"Lancet Haematol"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1038\/s41375-018-0143-8","volume":"32","author":"MM Patnaik","year":"2018","unstructured":"Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, et al. Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases. Leukemia. 2018;32:2512\u20138.","journal-title":"Leukemia"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.clml.2017.06.029","volume":"17","author":"A Rivera Duarte","year":"2017","unstructured":"Rivera Duarte A, Armengol Alonso A, Sandoval Cartagena E, Tuna Aguilar E. Blastic transformation in Mexican population with chronic myelomonocytic leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:532\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","volume":"121","author":"E Such","year":"2013","unstructured":"Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood. 2013;121:3005\u201315.","journal-title":"Blood"},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1200\/JCO.22.00437","volume":"41","author":"R Itzykson","year":"2023","unstructured":"Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, et al. Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol. 2023;41:1888\u201397.","journal-title":"J Clin Oncol"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"95.e1","DOI":"10.1016\/j.bbmt.2020.10.007","volume":"27","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Bogdanov R, St\u00f6lzel F, Rautenberg C, Panagiota V, Becker H, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Transplant Cell Ther. 2021;27:95.e1\u2013e4.","journal-title":"Transplant Cell Ther"},{"key":"1359_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00387-y","volume":"10","author":"P Pophali","year":"2020","unstructured":"Pophali P, Matin A, Mangaonkar AA, Carr R, Binder M, Al-Kali A, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10:121.","journal-title":"Blood Cancer J"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood.2021015173","volume":"140","author":"M Robin","year":"2022","unstructured":"Robin M, de Wreede LC, Padron E, Bakunina K, Fenaux P, Koster L, et al. Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis. Blood. 2022;140:1408\u201318.","journal-title":"Blood"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1038\/bcj.2015.53","volume":"5","author":"E Padron","year":"2015","unstructured":"Padron E, Garcia-Manero G, Patnaik MM, Itzykson R, Lasho T, Nazha A, et al. An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J. 2015;5:e333\u2013e.","journal-title":"Blood Cancer J"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"R Itzykson","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428\u201336.","journal-title":"J Clin Oncol"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.beha.2019.101138","volume":"33","author":"M Robin","year":"2020","unstructured":"Robin M, Itzykson R. Contemporary treatment approaches to CMML\u2014is allogeneic HCT the only cure? Best Pract Res Clin Haematol. 2020;33:101138.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1182\/bloodadvances.2020003600","volume":"5","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Badbaran A, Beelen DW, Salit RB, St\u00f6lzel F, Rautenberg C, et al. A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Adv. 2021;5:1760\u20139.","journal-title":"Blood Adv"},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1182\/blood-2014-02-514760","volume":"124","author":"N Kekre","year":"2014","unstructured":"Kekre N, Antin JH. Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood. 2014;124:334\u201343.","journal-title":"Blood"},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41375-018-0302-y","volume":"33","author":"J Schetelig","year":"2019","unstructured":"Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, et al. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia. Leukemia. 2019;33:686\u201395.","journal-title":"Leukemia"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1182\/blood-2011-12-380162","volume":"119","author":"N Kr\u00f6ger","year":"2012","unstructured":"Kr\u00f6ger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood. 2012;119:5632\u20139.","journal-title":"Blood"},{"key":"1359_CR20","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2024-193827","volume":"144","author":"S Abedin","year":"2024","unstructured":"Abedin S, Lian Q, Martens MJ, Al Malki MHDMM, Elmariah H, Gooptu M, et al. Superiority of post-transplant cyclophosphamide-based graft versus host disease (GvHD) prophylaxis in patients 70 years and older: a BMT CTN 1703 post-hoc analysis. Blood. 2024;144:1042.","journal-title":"Blood"},{"key":"1359_CR21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"1359_CR22","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","volume":"6","author":"AEC Broers","year":"2022","unstructured":"Broers AEC, de Jong CN, Bakunina K, Hazenberg MD, van Marwijk Kooy M, de Groot MR, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022;6:3378\u201385.","journal-title":"Blood Adv"},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1182\/blood-2024-199783","volume":"144","author":"K Hassan","year":"2024","unstructured":"Hassan K, Baranwal A, Mangaonkar AA, Hefazi M, Matin A, Litzow MR, et al. Risk of relapse post reduced intensity conditioning allogeneic stem cell transplant in patients with high-risk myeloid neoplasms based on Ptcy vs. TAC\/MTX Gvhd prophylaxis. Blood. 2024;144:4918.","journal-title":"Blood"},{"key":"1359_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1159\/000516655","volume":"161","author":"J McGowan-Jordan","year":"2021","unstructured":"McGowan-Jordan J, Hastings R, Moore S. Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): some thoughts, by T. Liehr. Cytogenet Genome Res. 2021;161:225\u20136.","journal-title":"Cytogenet Genome Res"},{"key":"1359_CR26","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2016-05-714030","volume":"128","author":"C Elena","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, Meggendorfer M, Germing U, Rizzo E, et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016;128:1408\u201317.","journal-title":"Blood"},{"key":"1359_CR27","doi-asserted-by":"crossref","unstructured":"Tefferi A, Fathima S, Abdelmagid M, Alsugair A, Aperna F, Rezasoltani M, et al. BLAST: a globally applicable and molecularly versatile survival model for chronic myelomonocytic leukemia. Blood. 2025;146:874\u20136.","DOI":"10.1182\/blood.2024027170"},{"key":"1359_CR28","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"1359_CR29","unstructured":"Karnofsky D, Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. pp. 191\u2013205."},{"key":"1359_CR30","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:642\u20139.","journal-title":"Transplant Cell Ther"},{"key":"1359_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","volume":"125","author":"SG Holtan","year":"2015","unstructured":"Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333\u20138.","journal-title":"Blood"},{"key":"1359_CR32","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.13576","volume":"171","author":"A Symeonidis","year":"2015","unstructured":"Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, et al. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol. 2015;171:239\u201346.","journal-title":"Br J Haematol"},{"key":"1359_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.90","volume":"5","author":"MM Patnaik","year":"2015","unstructured":"Patnaik MM, Wassie EA, Padron E, Onida F, Itzykson R, Lasho TL, et al. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome. Blood Cancer J. 2015;5:e270.","journal-title":"Blood Cancer J"},{"key":"1359_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.bbmt.2017.01.078","volume":"23","author":"HD Liu","year":"2017","unstructured":"Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, et al. Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia. Biol Blood Marrow Transpl. 2017;23:767\u201375.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1359_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","volume":"17","author":"H Eissa","year":"2011","unstructured":"Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant. 2011;17:908\u201315.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1359_CR36","doi-asserted-by":"publisher","first-page":"991.e1","DOI":"10.1016\/j.jtct.2021.08.028","volume":"27","author":"E Wedge","year":"2021","unstructured":"Wedge E, Hansen JW, Dybedal I, Creignou M, Ejerblad E, Lorenz F, et al. Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: clinical and molecular genetic prognostic factors in a Nordic population. Transplant Cell Ther. 2021;27:991.e1\u2013e9.","journal-title":"Transplant Cell Ther"},{"key":"1359_CR37","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1182\/blood-2024-202536","volume":"144","author":"R Alyamany","year":"2024","unstructured":"Alyamany R, Alnughmush A, Remberger M, Michelis F, Law AD, Lam W, et al. Strength to endure: superiority of MAC over RIC in patients <65 years undergoing stem cell transplantation using ATG-Ptcy-CSA for Gvhd prophylaxis. Blood 2024;144:4863.","journal-title":"Blood"},{"key":"1359_CR38","doi-asserted-by":"publisher","first-page":"483 e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes\u2014long-term follow-up of the BMT CTN 0901 Clinical Trial. Transpl Cell Ther. 2021;27:483 e1\u2013e6.","journal-title":"Transpl Cell Ther"},{"key":"1359_CR39","doi-asserted-by":"publisher","first-page":"86.e1","DOI":"10.1016\/j.jtct.2021.11.013","volume":"28","author":"A Nagler","year":"2022","unstructured":"Nagler A, Labopin M, Dholaria B, Wu D, Choi G, Aljurf M, et al. Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide versus cyclosporine A and Methotrexate in matched sibling donor transplantation. Transpl Cell Ther. 2022;28:86.e1\u2013e8.","journal-title":"Transpl Cell Ther"},{"key":"1359_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.leukres.2015.12.009","volume":"41","author":"H Itonaga","year":"2016","unstructured":"Itonaga H, Iwanaga M, Aoki K, Aoki J, Ishiyama K, Ishikawa T, et al. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a nationwide retrospective study. Leuk Res. 2016;41:48\u201355.","journal-title":"Leuk Res"},{"key":"1359_CR41","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","volume":"25","author":"T Schroeder","year":"2019","unstructured":"Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transplant. 2019;25:1550\u20139.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01359-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:06:50Z","timestamp":1759759610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01359-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6753879\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MVS: Research funding to the institution from AbbVie, Astellas, Celgene, KURA Oncology, and Marker Therapeutics. AT is a co-editor of BCJ but was not involved in either the review or the decision process of the current paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of the Mayo Clinic (IRB protocol number:12-003574). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and Consent to participate"}}],"article-number":"157"}}